Posted on Monday, 16 April 2018

UNREST - View Complete Flyer


National Centre for Neuroimmuniology and Emerging Diseases

Brought to you by ME/CFS/FM Support Assoc. Qld Inc.: an expert guest speaker to discuss research to date and patient support for ME/CFS Myalgic Encephalomyalitis/ Chronic Fatigue Syndrome), followed by “Unrest” the award winning documentary from the Sundance International Film Festival.

" A complex story of hope and resilience, depicting the “hidden” patient experience of post-exertional crashes and touching on the worldwide impact of ME/CFS on patients, their families, the health care system and the tax-payer. (97 mins)”






Wed 16 May, 12pm to 2pm


QRME (Qld Rural Medical Education)
190 Hume Street


by the 11 May to MEFMTBA@BIGPOND.COM or Theresa on 0407 920929


Professor Sonya Marshall-Gradisnik PhD

is a professor of immunology was the first to demonstrate numerous immunological and genetic abnormalities in CFS/ME. She is internationally recognised for her major contribution into immunological and genetic indicators for potential onset of CFS/ME. She has a provisional patents for the early detection of CFS/ME with Professor Staines. Professor Marshall-Gradisnik and Professor Staines established the only CFS/ME medical and research clinic in Australia to foster improved diagnosis and management of this illness. She has received over $10 million dollars in competitive external grant funding and has been cited over 416 times since 2010.

Professor Donald Staines

is currently Co-Director, NCNED . His responsibilities include supervision of graduate students undertaking research. The research interests at NCNED include receptor and signalling deficits at external and intracellular levels. Professor Staines graduated MBBS in 1974 from the University of Queensland. He holds specialist qualifications as Fellow, Australasian Faculty of Public Health Medicine (FAFPHM) and Fellow, Australasian Faculty of Occupational and Environmental Medicine (AFOEM), Royal Australasian College of Physicians. He is a public health medicine specialist and has over 70 publications in fatigue-related illness.

It is estimated that a quarter of a million Australians of all ages, including children, suffer from CFS/ME ie about 1.2% of the population worldwide. Of these people about 60,000 people are bed or housebound, unable to work or participate in society and reliant on carers. Despite the readily measurable physiological abnormalities, many patients suffer from disbelief, stigma and hence a lack of adequate support from friends, family and governmental agencies.
Recent discoveries in ME/CFS The National Centre for Neuroimmunology and Emerging Diseases (NCNED), Griffith University, has made significant discoveries in the pathomechanism of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This debilitating illness presents as a multi-system condition affecting almost all physiological systems. It has been difficult to diagnose because of the unknown pathomechanism and the absence of a diagnostic test. Currently the illness is diagnosed by an international case definition (International Consensus Criteria or ICC) which is mostly a symptom based definition.

NCNED researchers have identified changes in gene structures called single nucleotide polymorphisms or SNPs, in critical calcium (Ca2+) ion channels called transient receptor potential ion channels (TRPs). These changes result in deficits in Ca2+ signalling, a vital component of cell function. Calcium signalling influences a wide array of cellular activity, such as gene regulation, biochemical function and other second messenger functions.

Consequently multiple body systems are affected and likely range from impaired cardiovascular function (such as postural orthostatic tachycardia syndrome or POTS), immune function (such as natural killer cell function), and neurological function. Specifically changes affecting the TRP melastatin family (TRPM) have been shown by NCNED researchers to exist in ME/CFS patients.

NCNED researchers are moving swiftly to investigate the potential application of these discoveries in a diagnostic test and to investigate potential treatments.